is waiting for the inflection point
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been here as long as you. It has been a never ending roller coaster ride. Cash out some at $30, but that is low for the potential of this company in my opinion.
I thought I was done buying, but had to pick up a few K more shares. You don't say stuff like this unless there is evidence to back it up. It is not a "we hope to" or "if" kind of statement.
"his vision and leadership around the commercial production and scale-up of CytoSorb has resulted in economies of scale and major efficiency improvements in both polymer and device manufacturing, taking blended CytoSorb gross margins from 60% to 80% in Q4 2019. This has, in turn, enabled us to rapidly respond to the increased need for CytoSorb around the globe during this COVID-19 pandemic, including here in the U.S. under the EUA."
Treatments or patients?
Where did this info come from?
Do we really have to go through this every single time one of these sales happens? This plan could have been setup years ago. What Is Rule 10b5-1?
Rule 10b5-1, established by the Securities and Exchange Commission (SEC) in 2000, allows insiders of publicly traded corporations to set up a trading plan for selling stocks they own. It is a clarification of Rule 10b-5 (sometimes written as Rule 10b5), created under the Securities and Exchange Act of 1934, which is the primary vehicle for investigation of securities fraud. Rule 10b5-1 allows major holders to sell a predetermined number of shares at a predetermined time. Many corporate executives use 10b5-1 plans to avoid accusations of insider trading.
With nothing open around here for about 6 weeks, my real hair is starting to resemble that of Bill the Cat.
It has been like this for a decade.
Wow. Great find!
Lakers, this is not just a Sepsis treatment board. Never mind a sepsis treatment board specifically for sepsis cause by gram negative bacteria. Cytosorb treats all sepsis cases regardless of cause or source. It treats excessive myoglobin from rhabdomyolysis. It treats excessive plasma free hemoglobin in cardiac surgery. It treats cytokine storm in CAR T-cell therapy, CV19, etc. It simply helps restore hemodynamic stability many many situations. But here you are, confused about why we talk about it on its message board rather than another companies gram negative bacteria caused sepsis treatment?
So you are confused about why we are talking about CYTOSORBENTS on the "Cytosorbent Corporation" message board rather than Spectral? Wow!
Man, I am sad he is not here to see it play out. I hope his wife held strong with his shares.
LOL. On reduced work schedule myself. Today was a furlough day. Just might have been a little day drinking while we were out fishing.
Don't give credit to the stock price, but instead CV-19 day drinking.
But Jacques, funds were not secured yesterday. It was just a regulatory step to be able to sell "from time to time" ATM (At the Market) shares. If someone is posting a calculation of how much dilution this is, that is just silly. It is for a set dollar amount not number of shares. $25 million selling as $8/share is about 3 million shares. But if they don't need the cash immediately, which I don't think they do, they are just setting them selves up to be able to sell at a higher share price. If the prices rises to $25/share, that is only 1 million shares of dilution instead of 3 million.
They are just planning ahead IMHO and a set $ amount vs. a set number of shares is existing-shareholder friendly.
IMHO, if you need to raise funds for growth, ATM sales is the most shareholder friendly way to do it. If they are raising funds to expand manufacturing capabilities and be poised to have additional studies ramped up for post-C19 days, this is a very good thing.
Dr. Chan and team have obviously been very busy, but it would be nice to see a summary of what they see the recent events could mean for the company in the coming year and what they think they can ramp manufacturing up to if demand increases quickly.
Was being converted to manufacturer Hemodefend, but I believe there was some kind of hold up with the fabrication of the equipment.
They don't normally play a role in Hospitals acquiring ventilators either, but we are in strange times right now.
How could we not with all the positive moves in the US? There was talk of advancement in Canada years ago and it just quietly disappeared for some reason.
Well, it is not a medical technology board, but instead an investment board. He may be annoying, but he is usually very careful about his posts. Even if they are about another company, they are technically about a potential competitor in the target market From an investment perspective, that is on topic. I have appealed to higher up's on this web site about posters like him before and that is the feedback I got. If I were to delete posts like his, it would likely get reversed.
CTSO has always been a small company with a novel product performing in the equivalent of a small town playhouse. No matter how spectacular the performance of the their star is, with a small audience the struggle to excel and grow is difficult. Exposure from C19 might be the big move up to Broadway. The Broadway audience will not base their investments on an anonymous poster on an internet board.
As moderators we are permitted to set the tone of the board. We can be very strict or flexible. I like to be super flexible and just remove dupe posts, spam and anything vulgar. Spectral is at least the same segment and his posts actually allow us to point out how Cytosorb is superior.
Thumbs up!
Folks, one other important detail to note. Stats on on Cytosorb use have ALWAYS been presented as "treatments". If a patient is very sick they could get 10 or more treatments. Maybe 3 average. What is unique about this interview is that Dr. Chan states that Cytosorb has been used on over 200 "PATIENTS". Dr. Chan has always been very careful about the words he uses. That could mean anywhere from 200 to 600+ treatments for just C19 patients in the last 3 months. Never mind other illnesses and indications. Now it is opening up for wider use in the US. This could be huge.
New York was doing an emergency call out for ventilators. Ventilators are used far less frequently than dialysis machines. There are dialysis centers everywhere! They should be able to be sourced quickly in an emergency.
Sounds just like the AZ case recently published. Happy that ECMO worked for him, but read the ECMO story, they call it a rare treatment option. Cytosorb works in many companies standard dialysis machines. Not many ECMO machines around. Mostly in University hospitals and used when rarely needed. You also know that Richard Bartlett, the pioneer of ECMO was the Cytosorbents CMO for many years, right?
I saw another story where it mentions it was ECMO plus that arthritis/cancer drug. I forget what is was called though.
I did not know that about heparin. I hope it does not hurt CRMD's progress towards regulatory approval.
Probably legal. I think it was been used on a child as young as 4. I think the limiting factor is simply blood volume. It would probably difficult to use an a newborn.
Cytosorb XL is the new adsorber being designed to also adsorb endotoxins which are from gram negative bacterial infections. Sepsis/cytokine storm does not just originate from gram negative bacteria.
I may be off, but wasn't $8.00 the success fee trigger with Bridge Bank? Strange coincidence if it was.
I am sad that Bertha never got to see that FDA letter.
There was a poster and larger shareholder on the old Yahoo board who posted the history of their attempts nearly a decade ago. I believe it was a membrane solution that simply could not absorb enough cytokines to make a difference. Perhaps it was not a case of if you can't beat them then join them but if you cant beat them starve them until they need you to take them over to survive.
I have exchanged email with Dr. Chan a few times over the years. One email questioned the relationship with Fresenius and if their marketing interests was genuine. That was about 4-5 years ago. He has not responded to an email since.
Not a fan of how they have supported the company in the EU, but Fresenius has a huge infrastructure in the US.
Should have been approved for EAP 5 years ago. If it was, manufacturing capacity would probably be 50 times what it is now. The EAP denial is what needs to be investigated.
The media reports Cytokine Storm as "complications" from <blank>.
Whole blood treatment vs. plasma treatment that requires a ~$100k machine. Also a $1K treatment cost vs. $2.5K. Which would you choose? IMHO, Cytosorb all day long.
This is far better than 1000 trade shows or medical conferences for exposure in the US. When there are success stories it is going to be pretty difficult to shut it down once the pandemic passes. This is the ultimate fast track.
As far as marketing is concerned, I think supply rather than demand could be the problem.
As far as sales vs. giving away at cost. Think about taxes. They have been selling NOL tax credits for years. I'm sure it hits taxes as value rather than cost.
So the letter released yesterday was simply granting what we supposedly already had? I think not.
https://www.fda.gov/media/136866/download